Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 1997

View Archived Issues

Oligonucleotide compound in development for HIV-1 at Sankyo

Octreotide assessed in treatment of restenosis in VERAS study

Glutarimide tachykinin antagonists reported by Pfizer

CCK-A antagonists for the treatment of pancreatitis

New carbapenem derivatives described by Sankyo

Boehringer Ingelheim presents compounds active against mutant HIV-1 RT

Worldwide agreement between Aradigm and SKB for AERx Pain Management System

Myriad discovers gene's role as tumor suppressor

Periodontal tissue monitor kit launched in U.S.

Mylan receives FDA approval for generic verapamil

Celgene studies chirally pure mexiletine for relief of neuropathic pain

Vical licenses gene delivery technology to RPR

New antineoplastic cryptophycin derivatives

Merck's new fibrinogen receptor antagonists

Roussel Uclaf develops estrogenic compounds

Quadrant, Scherer to develop new oral delivery technology

Pamidronate evaluated as potential therapy for bone cancer

Significant research efforts center on new ketolide at Hoechst Marion Roussel

Flocor pivotal trial supported by FDA grant

CFC-222: a promising therapeutic for bacterial infections

Results from phase I trials with ISIS-3521/CGP-64128A reported

Mutual recognition approval obtained for Astra's angiotensin II blocker

Mechanism of action of oxazolidinones elucidated

Sugen expands SU-101 clinical trials

Neuroprotective effects of PNU-101017 in gerbil model

Cell pathway discovery holds potential for new anticancer treatments

Preliminary results from study of MultiKine in head and neck cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...